UNSPSC 51352414: Ethinyl estradiol/norelgestromin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352414 Ethinyl estradiol/norelgestromin is a Commodity code covering a specific oral contraceptive active-pharmaceutical combination that state and local health agencies procure through pharmacy benefit programs, cooperative purchasing alliances, and direct-to-manufacturer contracting arrangements. The work being solicited includes supply agreements for generic and branded formulations of this contraceptive product, with vendors expected to provide comprehensive pricing, maintain compliance with cGMP and Drug Supply Chain Security Act standards, and distribute through authorized pharmaceutical wholesalers or direct-to-state channels. Issuing bodies for this code span state health departments, multistate cooperative purchasing alliances, and Medicaid agencies seeking to manage contraceptive formulary costs and ensure consistent supply to eligible populations through state employee health plans, public health clinics, and Medicaid-covered beneficiaries.

Recent activity appears concentrated in the upper Midwest and Texas. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026, with a March 26, 2026, response deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon; the RFP requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program seeking to establish direct contracts between the state and pharmaceutical manufacturers outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler arrangements, with focus on negotiated net pricing and outcomes-based contracting models.